BioSpace News Archive

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Jennifer Towne, Ph.D., as Executive Vice President and Chief Scientific Officer, effective November 6, 2023.

Avilar Therapeutics today announced it will present new preclinical data from its ATAC (ASGPR Targeting Chimera) degrader platform at the sixth annual Targeted Protein Degradation Summit being held in Boston on October 30 – November 2, 2023.

ANI Pharmaceuticals, Inc. announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will participate at two upcoming healthcare conferences as follows.

Passage Bio, Inc. today announced that William Chou, M.D., president and chief executive officer, will participate in a fireside chat at Guggenheim’s 5th Annual Inflammation, Neurology & Immunology Conference on Monday, November 6, 2023 at 2:30 p.m. ET.

Tonix Pharmaceuticals Holding Corp. announced data from two oral presentations which were delivered recently at the ACS Clinical Congress 2023, and The IPITA, the International Xenotransplantation Association, and the Cell Transplant and Regenerative Medicine Society Joint Congress by faculty at the Center for Transplantation Sciences, Massachusetts General Hospital in October 2023.

Pharvaris announced the acceptance of two abstracts for ePoster presentation at the American College of Allergy, Asthma & Immunology 2023 Annual Scientific Meeting, to be held from November 9-13, 2023, at the Anaheim Convention Center in Anaheim, CA.

Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced that the Company will participate in two investor conferences in November.

Voyager Therapeutics, Inc. today announced it will report third quarter 2023 financial and operating results after market close on Monday, November 6, 2023.

Augmedix announced today it will report financial results for the third quarter ended September 30, 2023, on Monday, November 6, 2023, after the market closes.

Burning Rock Biotech Limited is pleased to announce that the Company and Boehringer Ingelheim officially have signed the Master Service Agreement in the field of oncology companion diagnostics.